Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $66.67

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $66.6667.

RVPH has been the subject of a number of research reports. Maxim Group lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. D. Boral Capital lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC bought a new position in shares of Reviva Pharmaceuticals during the second quarter worth $1,026,000. Millennium Management LLC lifted its position in Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares during the last quarter. Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals by 87.6% during the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after purchasing an additional 489,711 shares during the last quarter. State Street Corp lifted its position in Reviva Pharmaceuticals by 202.4% during the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in Reviva Pharmaceuticals by 63.6% during the fourth quarter. XTX Topco Ltd now owns 164,291 shares of the company’s stock valued at $46,000 after purchasing an additional 63,893 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Price Performance

RVPH opened at $0.67 on Friday. The firm has a market cap of $8.78 million, a P/E ratio of -0.17 and a beta of 0.57. Reviva Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $17.20. The company has a 50 day simple moving average of $0.67 and a two-hundred day simple moving average of $3.85.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). Equities analysts anticipate that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.